TY - JOUR
T1 - The CLL comorbidity index in a population-based cohort
T2 - a tool for clinical care and research
AU - Rotbain, Emelie C
AU - Gordon, Max J
AU - Vainer, Noomi
AU - Frederiksen, Henrik
AU - Hjalgrim, Henrik
AU - Danilov, Alexey V
AU - Niemann, Carsten Utoft
N1 - Copyright © 2022 American Society of Hematology.
PY - 2022/4/26
Y1 - 2022/4/26
N2 - The chronic lymphocytic leukemia comorbidity index (CLL-CI) is an efficient, CLL-specific tool derived from the Cumulative Illness Rating Scale. The CLL-CI is based on the assessment of the organ systems found to be most strongly associated with event-free survival (EFS) in CLL: vascular, upper gastrointestinal, and endocrine, at the time of initiation of CLL therapy. The CLL-CI categorizes patients into low, intermediate, and high risk groups. In the present study, we have employed the CLL-CI in a population-based cohort comprising 4975 patients with CLL. We demonstrate that CLL-CI retains prognostic significance in this large cohort and is associated with overall survival (OS) and EFS from time of first therapy. Furthermore, CLL-CI associates with OS, EFS, and time to first treatment from diagnosis independently of the CLL International Prognostic Index. These findings support the use of the CLL-CI both in research and in clinical practice.
AB - The chronic lymphocytic leukemia comorbidity index (CLL-CI) is an efficient, CLL-specific tool derived from the Cumulative Illness Rating Scale. The CLL-CI is based on the assessment of the organ systems found to be most strongly associated with event-free survival (EFS) in CLL: vascular, upper gastrointestinal, and endocrine, at the time of initiation of CLL therapy. The CLL-CI categorizes patients into low, intermediate, and high risk groups. In the present study, we have employed the CLL-CI in a population-based cohort comprising 4975 patients with CLL. We demonstrate that CLL-CI retains prognostic significance in this large cohort and is associated with overall survival (OS) and EFS from time of first therapy. Furthermore, CLL-CI associates with OS, EFS, and time to first treatment from diagnosis independently of the CLL International Prognostic Index. These findings support the use of the CLL-CI both in research and in clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85129903802&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2021005716
DO - 10.1182/bloodadvances.2021005716
M3 - Journal article
C2 - 35008098
SN - 2473-9529
VL - 6
SP - 2701
EP - 2706
JO - Blood advances
JF - Blood advances
IS - 8
ER -